TJC-642

N/A

Report date: 2025/06/11 11:14:23
NME

Base Information

Drug NameTJC-642
Drug Alias Name3CL protease inhibitor (TaiwanJ Pharmaceuticals)TJC-0642TJC-642
ClassificationSmall molecules
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTaiwanj Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiwanj Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A